Anticancer therapy with checkpoint inhibitors: What, where and when?

Trends in Pharmacological Sciences

Volumn 32, Issue 5, 2011, Pages 308-316

  Garrett, Michelle D ^a   Collins, Ian ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (4 CHLOROPHENOXY)PHENYL] 1H BENZO[D]IMIDAZOLE 5 CARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; AZD 7762; CAMPTOTHECIN; CCT 241533; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHECKPOINT KINASE INHIBITOR; CHIR 124; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EXEL 9844; GEMCITABINE; IRINOTECAN; ISOGRANULATIMIDE; LY 2603618; PD 312852; PD 321852; PD 407824; PEMETREXED; PF 00477736; PROTEIN SERINE THREONINE KINASE INHIBITOR; PV 1019; SAR 020106; SB 218078; SCH 900776; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VRX 0466617; XL 844;

ACUTE LEUKEMIA; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL CYCLE ARREST; COLON CANCER; COLORECTAL CANCER; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; IC 50; IONIZING RADIATION; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; RADIOSENSITIZATION; SOLID TUMOR; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 79955720082     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2011.02.014     Document Type: Review

References (62)

1. Y. Dai, and S. Grant New insights into checkpoint kinase 1 in the DNA damaging response signalling network Clin. Cancer Res. 16 2010 376 383
2. T.H. Stracker Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response DNA Repair 8 2009 1047 1054
3. H.C. Reinhardt, and M.B. Yaffe Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2 Curr. Opin. Cell Biol. 21 2009 245 255
4. S. Leijen Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents Curr. Clin. Pharmacol. 5 2010 186 191
5. M.J. O'Connor Targeted cancer therapies based on the inhibition of DNA strand break repair Oncogene 26 2007 7816 7824 (Pubitemid 350242461)
6. J.W. Janetka Inhibitors of checkpoint kinases: from discovery to the clinic Curr. Opin. Drug Discov. Devel. 10 2007 473 486 (Pubitemid 47093131)
7. J.W. Janetka, and S. Ashwell Checkpoint kinase inhibitors: a review of the patent literature Expert Opin. Ther. Pat. 19 2009 165 197
8. N. Bucher, and C.D. Britten G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br. J. Cancer 98 2008 523 528 (Pubitemid 351214533)
9. C.X. Ma Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends Mol. Med. 17 2011 88 96
10. E.C. Busby The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1 Cancer Res. 60 2000 2108 2112 (Pubitemid 30225168)
11. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1 Cancer Res. 62 2002 5743 5748 (Pubitemid 35204730)
12. P. Workman, and I. Collins Probing the probes: fitness factors for small molecule tools Chem. Biol. 17 2010 561 577
13. S.D. Zabludoff AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther. 7 2008 2955 2966
14. A. Blasina Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol. Cancer Ther. 7 2008 2394 2404
15. A. Tse CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo Clin. Cancer Res. 13 2007 591 602 (Pubitemid 46225366)
16. M.I. Walton The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106 Mol. Cancer Ther. 9 2010 89 100
17. A.G. Jobson Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}- amide] J. Pharmacol. Exp. Ther. 331 2009 816 826
18. J.J. Caldwell Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2 J. Med. Chem. 54 2010 580 590
19. Y. Pommier Chk2 molecular interaction map and rationale for Chk2 inhibitors Clin. Cancer Res. 12 2005 2657 2661
20. L. Antoni CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat. Rev. Cancer 7 2007 925 936 (Pubitemid 350165855)
21. Z. Xiao Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy Mol. Cancer Ther. 5 2006 1935 1943 (Pubitemid 44336564)
22. Q. Wang UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53 J. Natl. Cancer Inst. 88 1996 956 965 (Pubitemid 26239383)
23. L. Carrassa Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53 Cell Cycle 3 2004 1177 1181 (Pubitemid 40268636)
24. 1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionising radiation and Chk1 inhibitors Cell Prolif. 43 2010 365 371
25. C.M. Sturgeon, and M. Roberge G2 checkpoint kinase inhibitors exert their radiosensitising effects prior to the G2/M transition Cell Cycle 6 2007 572 575 (Pubitemid 46440430)
26. C.M. Sturgeon Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage Mol. Cancer Ther. 5 2006 885 889
27. Y. Tao Radiosensitization by Chir-124, a selective CHK1 inhibitor. Effects of p53 and cell cycle checkpoints Cell Cycle 8 2009 1196 1205
28. K.L. Arienti Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles J. Med. Chem. 48 2005 1873 1885 (Pubitemid 40396318)
29. L. Carlessi Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Mol. Cancer Ther. 6 2007 935 944 (Pubitemid 46554563)
30. H. Takai Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription EMBO J. 21 2002 5195 5205
31. O. Riesterer A novel Chk1 inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe Invest. New Drugs 2009 10.1007/s10637-009-9361-2
32. J.B. Mitchell In vitro and in vivo radiation sensitization of human tumour cells by a novel checkpoint kinase inhibitor, AZD7762 Clin. Cancer Res. 16 2010 2076 2084
33. M.A. Morgan Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res. 70 2010 4972 4981
34. S. Arora RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells Gynecol. Oncol. 118 2010 220 227
35. J.M. Wagner, and L.M. Karnitz Cisplatin-induced DNA damage activates replication checkpoint signalling components that differentially affect tumour cell survival Mol. Pharmacol. 76 2009 208 214
36. S. Zenvirt Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents Oncogene 29 2010 6149 6159
37. I.M. Pires Oxaliplatin responses in colorectal cells are modulated by CHK2 kinase inhibitors Br. J. Pharmacol. 159 2010 1326 1338
38. S. McNeely Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase Cell Cycle 9 2010 995 1004
39. D.J. Matthews Pharmacological abrogation of S-phase checkpoint enhances the anti-tumour activity of gemcitabine in vivo Cell Cycle 6 2007 104 110 (Pubitemid 46173886)
40. D.O. Azorsa Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer J. Transl. Med. 7 2009 43
41. L.A. Parsels Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Mol. Cancer Ther. 8 2009 45 54
42. M. Ganzinelli Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil Clin. Cancer Res. 14 2008 5131 5141
43. R.G. Shao Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function Cancer Res. 57 1997 4029 4035
44. K. Flatten The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons J. Biol. Chem. 280 2005 14349 14355 (Pubitemid 40517339)
45. C. Conti The mammalian DNA replication elongation checkpoint. Implication of CHK1 and relationship with origin firing as determined by single DNA molecule and single cell analyses Cell Cycle 6 2007 2760 2767 (Pubitemid 350277167)
46. J.A. Seiler The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses Mol. Cell Biol. 27 2007 5806 5818 (Pubitemid 47257835)
47. V.E. Anderson CCT241533 is a potent and selective inhibitor of CHK2 which potentiates the cytotoxicity of PARP inhibitors Cancer Res. 71 2010 463 472
48. J. Tang Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1) Proc. Natl. Acad. Sci. U.S.A. 103 2006 11964 11969 (Pubitemid 44215794)
49. Z. Xiao Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics Int. J. Cancer 115 2005 528 538 (Pubitemid 40656709)
50. G. Zachos Chk1 is required for spindle checkpoint function Dev. Cell 12 2007 247 260 (Pubitemid 46193970)
51. C. Zhang PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts Clin. Cancer Res. 15 2009 4630 4640
52. C. Mitchell Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells Mol. Pharmacol. 78 2010 909 917
53. X.R. Lu A stronger DNA damage-induced G2 checkpoint due to over-activated CHK1 in the absence of PARP1 Cell Cycle 5 2006 2364 2370
54. N. McCabe Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res. 66 2006 8109 8115 (Pubitemid 44299177)
55. Y. Tao The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe Cell Cycle 8 2009 3172 3181
56. C.C. Chen CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway deficient tumors Mol. Cancer 8 2009 24
57. C. Cavelier Constitutive activation of the DNA damage signalling pathway in acute myeloid leukaemia with complex karyotype: potential importance in checkpoint targeting therapy Cancer Res. 69 2009 8652 8661
58. K.A. Cole RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma Proc. Natl. Acad. Sci. U.S.A. 108 2011 3336 3341
59. X. Jiang Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide Mol. Cancer Ther. 3 2004 1221 1227 (Pubitemid 39440167)
60. J.R. Jackson An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage Cancer Res. 60 2000 566 572 (Pubitemid 30094552)
61. B.D. Palmer 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution J. Med. Chem. 49 2006 4896 4911 (Pubitemid 44201048)
62. Guzi, T. et al. (2011) Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol. Cancer Ther. doi:10.1158/1535-7163.MCT-10-0928.